Fail Safe Cell Therapy

1-888-613-6862
info@pancella.com

News

  • panCELLa’s Exclusive FailSafe Cells Improve Cell Therapy Safety

    panCELLa is proud to announce the publication of “Linking a cell division and a suicide gene to define and improve cell therapy safety”  in the November 21st  2018 issue of Nature. Available online, you may view the article by visiting the Nature website. Cell therapies hold enormous promise of new treatment and cures...
  • panCELLa proud to collaborate in advancing cure for blindness

    panCELLa, in collaboration with the Foundation Fighting Blindness, looks forward to advancing the research from Dr. Nagy's lab to clinical trials.  For further details on Dr Nagy's breakthrough for treating AMD with a combination of cell and gene therapy, read the announcement here from the Foundation Fighting Blindness.
  • Interdisciplinary research team tackles remaining hurdles to using stem cells to reverse heart failure

    A story on one of the 19 University of Toronto Medicine By Design (MbD) projects using regenerative medicine to advance healthcare.  It is one of three projects currently being run by MbD that are using FailSafe.  This MbD project entitled  IMPROVING THE FUNCTION, INTEGRATION AND SAFETY OF STEM CELL-DERIVED CARDIOMYOCYTE...
  • panCELLa Inc. raises $1M in seed funding

    With the support of Chiefswood, panCELLa brings our exclusive FailSafe System to the market.  panCELLa offers a solution to the safety risks generally associated with cell therapies.  The exclusive "FailSafe Cell System"  ensures the safety of a cell therapy is irrefutable and measurable.  The “FailSafe System” does not impede the therapeutic...
  • Suicidal cells — Are they the key to safe cell therapy?

    Dr. Andras Nagy, a stem cell researcher at the Lunenfeld-Tanenbaum Research Institute in Toronto has been thinking a lot about risk. In his talk at the 2016 Till and McCulloch Meetings held in Whistler, BC last month, he explained the unique and innovative approach that his lab has developed to...
  • Pioneering Toronto scientist continues to demystify stem cells

    Dr. Andras Nagy’s team discovers a new class of stem cells that could help treat everything from Alzheimer’s to spinal cord injuries. When Mount Sinai Hospital researcher Dr. Andras Nagy initiated a huge project to demystify the process by which specialized cells become stem cells, he wasn’t expecting to discover a...
  • Cancer Treatment with NK Cell Lines: An Effective Alternative?

    Armand Keating, MD, FCRP(C), is Professor of Medicine, Director , Division of Hematology, Epstein Chair in Cell Therapy and Transplantation and a Professor in the Institute of Biomaterials and Biomedical Engineering at the University of Toronto. He is also Director of the Cell Therapy Program and the Orsino Cell Therapy...
  • The darker side of regenerative medicine: working toward safer stem cell therapies

    Stem cells have been widely touted as a source of great hope for their use in medicine, such as in the development of new drugs to prevent and treat illnesses like Parkinson’s disease, wound healing and spinal cord injury. But techniques for generating these highly malleable cells have also created...
  • Dr. Armand Keating installed as President-Elect of the American Society of Hematology

    At the Annual Meeting in San Diego, California earlier this week, Dr. Armand Keating was installed as the President-Elect of the American Society of Hematology (ASH). This is well-deserved recognition for Dr. Keating and his pioneering work in hematology and a tremendous honour for Canadian medicine.
  • Dr. Andras Nagy makes SCIENTIFIC AMERICA Top 10 Honor Roll

    Mount Sinai Hospital’s Dr. Andras Nagy has been selected for the first annual SCIENTIFIC AMERICAN Top 10 Honor Roll. The only Canadian selected for the article, Dr. Nagy shares the honour with U.S. President Barack Obama, Bill Gates, Michael Bloomberg and other luminaries in the June 2009 issue of the...